Published in Oncotarget on January 19, 2016
Akt isoform specific effects in ovarian cancer progression. Oncotarget (2016) 0.79
Stimulatory actions of IGF-I are mediated by IGF-IR cross-talk with GPER and DDR1 in mesothelioma and lung cancer cells. Oncotarget (2016) 0.78
Global cancer statistics. CA Cancer J Clin (2011) 185.92
TopHat: discovering splice junctions with RNA-Seq. Bioinformatics (2009) 81.13
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72
Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics (2014) 44.23
Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A (2001) 24.34
Open source clustering software. Bioinformatics (2004) 23.17
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol (2002) 17.85
Macrophage diversity enhances tumor progression and metastasis. Cell (2010) 13.41
Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science (2001) 11.22
Comprehensive molecular profiling of lung adenocarcinoma. Nature (2014) 11.02
Identification of novel transcripts in annotated genomes using RNA-Seq. Bioinformatics (2011) 8.05
Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem (2001) 7.10
Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. J Clin Invest (2003) 4.79
Structure, regulation and function of PKB/AKT--a major therapeutic target. Biochim Biophys Acta (2004) 4.11
Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest (2003) 4.06
Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res (2007) 3.13
Essential role of protein kinase B gamma (PKB gamma/Akt3) in postnatal brain development but not in glucose homeostasis. Development (2005) 3.02
Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med (2009) 2.73
Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci (2000) 2.52
Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat Med (2014) 2.26
Role of macrophages in tumour progression. Immunol Lett (2009) 2.07
Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis (2004) 1.92
A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer (2005) 1.79
Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene (1991) 1.79
Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol (2005) 1.64
Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res (2004) 1.60
Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol (2010) 1.58
Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol (2015) 1.56
Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation. Oncogene (2006) 1.44
Increased phospho-AKT (Ser(473)) expression in bronchial dysplasia: implications for lung cancer prevention studies. Cancer Epidemiol Biomarkers Prev (2003) 1.42
Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. Clin Cancer Res (2003) 1.38
The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Clin Cancer Res (2005) 1.38
Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. Am J Transl Res (2012) 1.37
Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer. Biochem Pharmacol (2014) 1.34
Diverse mechanisms of AKT pathway activation in human malignancy. Curr Cancer Drug Targets (2013) 1.33
Phospho-akt expression is associated with a favorable outcome in non-small cell lung cancer. Clin Cancer Res (2005) 1.30
Insulin-like growth factor expression in human cancer cell lines. J Biol Chem (1996) 1.28
The neurotrophic receptor TrkB: a drug target in anti-cancer therapy? Cell Mol Life Sci (2006) 1.25
Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancer. Cancer Gene Ther (2003) 1.20
Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res (1992) 1.19
The role of matrix metalloproteinase 2 on the survival of patients with non-small cell lung cancer: a systematic review with meta-analysis. Cancer Invest (2010) 1.18
Inhibitory effects of andrographolide on migration and invasion in human non-small cell lung cancer A549 cells via down-regulation of PI3K/Akt signaling pathway. Eur J Pharmacol (2010) 1.17
Matrix metalloproteinase and its drug targets therapy in solid and hematological malignancies: an overview. Mutat Res (2013) 1.17
Akt1 deletion prevents lung tumorigenesis by mutant K-ras. Oncogene (2011) 1.17
The role of p53 in treatment responses of lung cancer. Biochem Biophys Res Commun (2005) 1.16
PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes. Acta Pharmacol Sin (2012) 1.15
Diagnostic utility of LunX mRNA in peripheral blood and pleural fluid in patients with primary non-small cell lung cancer. BMC Cancer (2008) 1.15
Role of secretoglobin 3A2 in lung development. Am J Respir Crit Care Med (2008) 1.12
Expression of TrkB and BDNF is associated with poor prognosis in non-small cell lung cancer. Lung Cancer (2012) 1.10
IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations. Sci Rep (2013) 1.07
Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydil-inositol-3 kinase. PLoS One (2012) 1.06
Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality. Physiol Rev (2015) 1.03
Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor. PLoS One (2014) 1.02
Structure and function of the insulin-like growth factor I receptor. Breast Cancer Res Treat (1998) 1.01
Diverse prognostic roles of Akt isoforms, PTEN and PI3K in tumor epithelial cells and stromal compartment in non-small cell lung cancer. Anticancer Res (2009) 1.01
The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor. Int J Cancer (2014) 0.99
Opposing functions of Akt isoforms in lung tumor initiation and progression. PLoS One (2014) 0.99
Molecular histology of lung cancer: from targets to treatments. Cancer Treat Rev (2015) 0.99
ICAM-3 enhances the migratory and invasive potential of human non-small cell lung cancer cells by inducing MMP-2 and MMP-9 via Akt and CREB. Int J Oncol (2010) 0.98
Neurotrophin receptor TrkB promotes lung adenocarcinoma metastasis. Proc Natl Acad Sci U S A (2014) 0.98
Genetic modifiers of EGFR dependence in non-small cell lung cancer. Proc Natl Acad Sci U S A (2014) 0.97
Secretoglobin 3A2 suppresses bleomycin-induced pulmonary fibrosis by transforming growth factor beta signaling down-regulation. J Biol Chem (2011) 0.97
Extending survival of stage IV non-small cell lung cancer. Semin Oncol (2013) 0.97
Role for membrane and secreted insulin-like growth factor-binding protein-2 in the regulation of insulin-like growth factor action in lung tumors. Cancer Res (1993) 0.96
Non-small cell lung cancers frequently express phosphorylated Akt; an immunohistochemical study. APMIS (2002) 0.95
Quantitation of pyridyloxobutyl-DNA adducts in tissues of rats treated chronically with (R)- or (S)-N'-nitrosonornicotine (NNN) in a carcinogenicity study. Chem Res Toxicol (2013) 0.93
Suppression of tumor cell invasiveness and in vivo tumor growth by microRNA-874 in non-small cell lung cancer. Biochem Biophys Res Commun (2013) 0.93
Loss of tumorigenicity and metastatic potential in carcinoma cells expressing the extracellular domain of the type 1 insulin-like growth factor receptor. Cancer Res (2004) 0.92
Oxidative stress enhances Axl-mediated cell migration through an Akt1/Rac1-dependent mechanism. Free Radic Biol Med (2013) 0.91
The AKT genes and their roles in various disorders. Am J Med Genet A (2013) 0.91
GOLPH3 overexpression is closely correlated with poor prognosis in human non-small cell lung cancer and mediates its metastasis through upregulating MMP-2 and MMP-9. Cell Physiol Biochem (2015) 0.90
MicroRNA-29b attenuates non-small cell lung cancer metastasis by targeting matrix metalloproteinase 2 and PTEN. J Exp Clin Cancer Res (2015) 0.90
PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies. Oncotarget (2015) 0.90
Expression of secretoglobin3A2 (SCGB3A2) in primary pulmonary carcinomas. Fukushima J Med Sci (2008) 0.90
Activated Akt expression has significant correlation with EGFR and TGF-alpha expressions in stage I NSCLC. Anticancer Res (2004) 0.90
The role of the dysfunctional akt-related pathway in cancer: establishment and maintenance of a malignant cell phenotype, resistance to therapy, and future strategies for drug development. Scientifica (Cairo) (2013) 0.89
Roles of AKT1 and AKT2 in non-small cell lung cancer cell survival, growth, and migration. Cancer Sci (2011) 0.88
Acquired resistance to targeted therapies in advanced non-small cell lung cancer: new strategies and new agents. Am Soc Clin Oncol Educ Book (2013) 0.87
Targeting LUNX inhibits non-small cell lung cancer growth and metastasis. Cancer Res (2015) 0.87
Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma. Lung Cancer (2006) 0.87
Claudin 4 knockout mice: normal physiological phenotype with increased susceptibility to lung injury. Am J Physiol Lung Cell Mol Physiol (2014) 0.86
Modulation of response to radiation of human lung cancer cells following insulin-like growth factor 1 receptor inactivation. Cancer Lett (2004) 0.86
Suppression of IGHG1 gene expression by siRNA leads to growth inhibition and apoptosis induction in human prostate cancer cell. Mol Biol Rep (2012) 0.85
The presence of IGHG1 in human pancreatic carcinomas is associated with immune evasion mechanisms. Pancreas (2011) 0.85
Inhibition of akt/protein kinase B signaling by naltrindole in small cell lung cancer cells. Cancer Res (2004) 0.85
Immunohistochemical expression of neurotrophic tyrosine kinase receptors 1 and 2 in lung carcinoma: potential discriminators between squamous and nonsquamous subtypes. Arch Pathol Lab Med (2011) 0.85
Correlations of lysyl oxidase with MMP2/MMP9 expression and its prognostic value in non-small cell lung cancer. Int J Clin Exp Pathol (2014) 0.85
Significance of combined detection of LunX mRNA and tumor markers in diagnosis of lung carcinoma. Chin J Cancer Res (2014) 0.84
Loss of Akt1 or Akt2 delays mammary tumor onset and suppresses tumor growth rate in MTB-IGFIR transgenic mice. BMC Cancer (2013) 0.84
Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy. Tumour Biol (2010) 0.84
Type I insulin-like growth factor receptor induces pulmonary tumorigenesis. Neoplasia (2009) 0.84
LUNX mRNA-positive cells at different time points predict prognosis in patients with surgically resected nonsmall cell lung cancer. Transl Res (2013) 0.84
The epidermal growth factor receptor (EGRF) in lung cancer. Transl Respir Med (2015) 0.83
Bostrycin inhibits proliferation of human lung carcinoma A549 cells via downregulation of the PI3K/Akt pathway. J Exp Clin Cancer Res (2011) 0.83
Cigarette smoke-induced alveolar epithelial-mesenchymal transition is mediated by Rac1 activation. Biochim Biophys Acta (2014) 0.83
Targeted therapy in NSCLC driven by HER2 insertions. Transl Lung Cancer Res (2014) 0.82
Monoclonal antibody alpha IR-3 inhibits non-small cell lung cancer growth in vitro and in vivo. J Cell Biochem Suppl (1996) 0.82
Involvement of the Akt/mTOR pathway on EGF-induced cell transformation. Mol Carcinog (2003) 0.82
Insulin-like growth factor family and combined antisense approach in therapy of lung carcinoma. Mol Med (2002) 0.81